Last reviewed · How we verify
Shanghai Zerun Biotechnology Co.,Ltd — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
2 Phase 3
0 Phase 2
3 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| HPV-16/18 vaccine | HPV-16/18 vaccine | phase 3 | Prophylactic vaccine | HPV-16 and HPV-18 L1 capsid proteins | Oncology / Immunology | |
| Zerun HPV-9 | Zerun HPV-9 | phase 3 | vaccine | Infectious Disease |
Therapeutic area mix
- Infectious Disease · 1
- Oncology / Immunology · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- GlaxoSmithKline · 2 shared drug classes
- Murdoch Childrens Research Institute · 2 shared drug classes
- Aeras · 1 shared drug class
- Aimei Vacin BioPharm (Zhejiang) Co., Ltd. · 1 shared drug class
- Alba Maria Ropero · 1 shared drug class
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. · 1 shared drug class
- Asoc. Prof. Erdoğan Selçuk Şeber · 1 shared drug class
- Aga Khan University · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Shanghai Zerun Biotechnology Co.,Ltd:
- Shanghai Zerun Biotechnology Co.,Ltd pipeline updates — RSS
- Shanghai Zerun Biotechnology Co.,Ltd pipeline updates — Atom
- Shanghai Zerun Biotechnology Co.,Ltd pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Shanghai Zerun Biotechnology Co.,Ltd — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/shanghai-zerun-biotechnology-co-ltd. Accessed 2026-05-16.